nodes	percent_of_prediction	percent_of_DWPC	metapath
Maraviroc—CCR5—multiple sclerosis	0.647	1	CbGaD
Maraviroc—CYP3A4—Fingolimod—multiple sclerosis	0.0308	0.246	CbGbCtD
Maraviroc—CYP3A4—Methylprednisolone—multiple sclerosis	0.0198	0.158	CbGbCtD
Maraviroc—CYP3A4—Triamcinolone—multiple sclerosis	0.015	0.12	CbGbCtD
Maraviroc—CYP3A4—Mitoxantrone—multiple sclerosis	0.0145	0.116	CbGbCtD
Maraviroc—CYP3A4—Betamethasone—multiple sclerosis	0.0129	0.103	CbGbCtD
Maraviroc—CYP3A4—Prednisolone—multiple sclerosis	0.0127	0.102	CbGbCtD
Maraviroc—CYP3A4—Prednisone—multiple sclerosis	0.012	0.0959	CbGbCtD
Maraviroc—CYP3A4—Dexamethasone—multiple sclerosis	0.00749	0.0599	CbGbCtD
Maraviroc—CCR5—Binding and entry of HIV virion—CD4—multiple sclerosis	0.00445	0.052	CbGpPWpGaD
Maraviroc—CCR5—IL12-mediated signaling events—TBX21—multiple sclerosis	0.00282	0.033	CbGpPWpGaD
Maraviroc—CCR5—IL12-mediated signaling events—EOMES—multiple sclerosis	0.00282	0.033	CbGpPWpGaD
Maraviroc—CCR5—Chemokine receptors bind chemokines—CXCL13—multiple sclerosis	0.00207	0.0242	CbGpPWpGaD
Maraviroc—CCR5—Chemokine receptors bind chemokines—CCR1—multiple sclerosis	0.00207	0.0242	CbGpPWpGaD
Maraviroc—CCR5—IL12-mediated signaling events—IL12A—multiple sclerosis	0.00195	0.0229	CbGpPWpGaD
Maraviroc—CCR5—GPCRs, Other—S1PR1—multiple sclerosis	0.0019	0.0222	CbGpPWpGaD
Maraviroc—CCR5—IL12-mediated signaling events—HLA-DRA—multiple sclerosis	0.00178	0.0208	CbGpPWpGaD
Maraviroc—CCR5—Peptide GPCRs—CCR1—multiple sclerosis	0.00165	0.0193	CbGpPWpGaD
Maraviroc—CCR5—Early Phase of HIV Life Cycle—CD4—multiple sclerosis	0.00163	0.0191	CbGpPWpGaD
Maraviroc—CCR5—TCR Signaling Pathway—CBLB—multiple sclerosis	0.0015	0.0175	CbGpPWpGaD
Maraviroc—CCR5—Chemokine receptors bind chemokines—CCL3—multiple sclerosis	0.00147	0.0172	CbGpPWpGaD
Maraviroc—CCR5—IL12-mediated signaling events—CCL3—multiple sclerosis	0.00139	0.0163	CbGpPWpGaD
Maraviroc—CCR5—Chemokine receptors bind chemokines—CXCR3—multiple sclerosis	0.00137	0.016	CbGpPWpGaD
Maraviroc—CCR5—IL12-mediated signaling events—STAT4—multiple sclerosis	0.00134	0.0157	CbGpPWpGaD
Maraviroc—CCR5—Chemokine receptors bind chemokines—CCR2—multiple sclerosis	0.00133	0.0156	CbGpPWpGaD
Maraviroc—CCR5—IL12-mediated signaling events—IL12B—multiple sclerosis	0.00123	0.0144	CbGpPWpGaD
Maraviroc—CCR5—TCR Signaling Pathway—MALT1—multiple sclerosis	0.00117	0.0137	CbGpPWpGaD
Maraviroc—CCR5—Chemokine receptors bind chemokines—CXCL10—multiple sclerosis	0.00111	0.0129	CbGpPWpGaD
Maraviroc—CCR5—Peptide GPCRs—CXCR3—multiple sclerosis	0.00109	0.0128	CbGpPWpGaD
Maraviroc—CCR5—Peptide GPCRs—CCR2—multiple sclerosis	0.00106	0.0125	CbGpPWpGaD
Maraviroc—CCR5—TCR Signaling Pathway—IL17A—multiple sclerosis	0.000955	0.0112	CbGpPWpGaD
Maraviroc—CCR5—Chemokine receptors bind chemokines—CCL5—multiple sclerosis	0.000952	0.0111	CbGpPWpGaD
Maraviroc—CCR5—GPCRs, Other—CXCR3—multiple sclerosis	0.000928	0.0109	CbGpPWpGaD
Maraviroc—CCR5—TCR Signaling Pathway—CD28—multiple sclerosis	0.000927	0.0108	CbGpPWpGaD
Maraviroc—CCR5—G alpha (i) signalling events—S1PR1—multiple sclerosis	0.000889	0.0104	CbGpPWpGaD
Maraviroc—CCR5—IL12-mediated signaling events—CD8A—multiple sclerosis	0.000887	0.0104	CbGpPWpGaD
Maraviroc—CCR5—IL12-mediated signaling events—IL4—multiple sclerosis	0.000873	0.0102	CbGpPWpGaD
Maraviroc—CCR5—GPCRs, Other—CNR1—multiple sclerosis	0.000833	0.00974	CbGpPWpGaD
Maraviroc—CCR5—IL12-mediated signaling events—IL2RA—multiple sclerosis	0.0008	0.00936	CbGpPWpGaD
Maraviroc—CCR5—IL12-mediated signaling events—HLA-A—multiple sclerosis	0.000791	0.00925	CbGpPWpGaD
Maraviroc—CCR5—Peptide ligand-binding receptors—CCR1—multiple sclerosis	0.000777	0.00909	CbGpPWpGaD
Maraviroc—CCR5—Peptide ligand-binding receptors—CXCL13—multiple sclerosis	0.000777	0.00909	CbGpPWpGaD
Maraviroc—CCR5—G alpha (i) signalling events—RGS1—multiple sclerosis	0.000756	0.00885	CbGpPWpGaD
Maraviroc—CCR5—IL12-mediated signaling events—HLA-DRB1—multiple sclerosis	0.000723	0.00845	CbGpPWpGaD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—S1PR1—multiple sclerosis	0.000707	0.00827	CbGpPWpGaD
Maraviroc—CCR5—GPCRs, Class A Rhodopsin-like—GPR65—multiple sclerosis	0.000665	0.00778	CbGpPWpGaD
Maraviroc—CCR5—Chemokine receptors bind chemokines—CCL2—multiple sclerosis	0.000656	0.00767	CbGpPWpGaD
Maraviroc—CCR5—G alpha (i) signalling events—CXCL13—multiple sclerosis	0.000656	0.00767	CbGpPWpGaD
Maraviroc—CCR5—G alpha (i) signalling events—CCR1—multiple sclerosis	0.000656	0.00767	CbGpPWpGaD
Maraviroc—CCR5—TCR Signaling Pathway—CD8A—multiple sclerosis	0.000642	0.00751	CbGpPWpGaD
Maraviroc—CCR5—GPCRs, Class A Rhodopsin-like—CCR1—multiple sclerosis	0.000609	0.00712	CbGpPWpGaD
Maraviroc—CCR5—TCR Signaling Pathway—FAS—multiple sclerosis	0.000582	0.0068	CbGpPWpGaD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—GPR65—multiple sclerosis	0.00057	0.00667	CbGpPWpGaD
Maraviroc—CCR5—IL12-mediated signaling events—TYK2—multiple sclerosis	0.000564	0.00659	CbGpPWpGaD
Maraviroc—CCR5—Peptide ligand-binding receptors—CCL3—multiple sclerosis	0.000554	0.00648	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—S1PR1—multiple sclerosis	0.000539	0.0063	CbGpPWpGaD
Maraviroc—CCR5—IL12-mediated signaling events—IFNG—multiple sclerosis	0.000528	0.00617	CbGpPWpGaD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—CXCL13—multiple sclerosis	0.000521	0.0061	CbGpPWpGaD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—CCR1—multiple sclerosis	0.000521	0.0061	CbGpPWpGaD
Maraviroc—CCR5—Peptide ligand-binding receptors—CXCR3—multiple sclerosis	0.000515	0.00602	CbGpPWpGaD
Maraviroc—CCR5—IL12-mediated signaling events—CD4—multiple sclerosis	0.00051	0.00596	CbGpPWpGaD
Maraviroc—CCR5—spinal cord—multiple sclerosis	0.000508	0.289	CbGeAlD
Maraviroc—CCR5—Peptide ligand-binding receptors—CCR2—multiple sclerosis	0.000501	0.00586	CbGpPWpGaD
Maraviroc—CCR5—IL12-mediated signaling events—IL1B—multiple sclerosis	0.000471	0.00551	CbGpPWpGaD
Maraviroc—CCR5—IL12-mediated signaling events—IL2—multiple sclerosis	0.000469	0.00549	CbGpPWpGaD
Maraviroc—CCR5—HIV Infection—CD28—multiple sclerosis	0.00046	0.00538	CbGpPWpGaD
Maraviroc—CCR5—G alpha (i) signalling events—CXCR3—multiple sclerosis	0.000434	0.00508	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—GPR65—multiple sclerosis	0.000434	0.00508	CbGpPWpGaD
Maraviroc—CCR5—nervous system—multiple sclerosis	0.000428	0.243	CbGeAlD
Maraviroc—CCR5—G alpha (i) signalling events—CCR2—multiple sclerosis	0.000423	0.00494	CbGpPWpGaD
Maraviroc—CCR5—GPCRs, Class A Rhodopsin-like—PTGER4—multiple sclerosis	0.000417	0.00488	CbGpPWpGaD
Maraviroc—CCR5—Peptide ligand-binding receptors—CXCL10—multiple sclerosis	0.000416	0.00487	CbGpPWpGaD
Maraviroc—CCR5—central nervous system—multiple sclerosis	0.000412	0.234	CbGeAlD
Maraviroc—CCR5—GPCRs, Class A Rhodopsin-like—CXCR3—multiple sclerosis	0.000403	0.00472	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—CCR1—multiple sclerosis	0.000397	0.00464	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—CXCL13—multiple sclerosis	0.000397	0.00464	CbGpPWpGaD
Maraviroc—CCR5—IL12-mediated signaling events—STAT3—multiple sclerosis	0.000395	0.00462	CbGpPWpGaD
Maraviroc—CCR5—GPCRs, Class A Rhodopsin-like—CCR2—multiple sclerosis	0.000392	0.00459	CbGpPWpGaD
Maraviroc—CCR5—G alpha (i) signalling events—CNR1—multiple sclerosis	0.00039	0.00456	CbGpPWpGaD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—CCL3—multiple sclerosis	0.000371	0.00435	CbGpPWpGaD
Maraviroc—CCR5—TCR Signaling Pathway—CD4—multiple sclerosis	0.000368	0.00431	CbGpPWpGaD
Maraviroc—CCR5—GPCRs, Class A Rhodopsin-like—CNR1—multiple sclerosis	0.000362	0.00423	CbGpPWpGaD
Maraviroc—CCR5—Peptide ligand-binding receptors—CCL5—multiple sclerosis	0.000358	0.00419	CbGpPWpGaD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—PTGER4—multiple sclerosis	0.000358	0.00418	CbGpPWpGaD
Maraviroc—CCR5—G alpha (i) signalling events—CXCL10—multiple sclerosis	0.000351	0.00411	CbGpPWpGaD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—CXCR3—multiple sclerosis	0.000345	0.00404	CbGpPWpGaD
Maraviroc—CCR5—TCR Signaling Pathway—IL1B—multiple sclerosis	0.00034	0.00398	CbGpPWpGaD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—CCR2—multiple sclerosis	0.000336	0.00393	CbGpPWpGaD
Maraviroc—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	0.000331	0.00387	CbGpPWpGaD
Maraviroc—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	0.000331	0.00387	CbGpPWpGaD
Maraviroc—CCR5—brain—multiple sclerosis	0.000327	0.186	CbGeAlD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—CNR1—multiple sclerosis	0.00031	0.00363	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—S1PR1—multiple sclerosis	0.000304	0.00356	CbGpPWpGaD
Maraviroc—CCR5—G alpha (i) signalling events—CCL5—multiple sclerosis	0.000302	0.00354	CbGpPWpGaD
Maraviroc—CYP3A4—Irinotecan Pathway—BCHE—multiple sclerosis	0.000293	0.00343	CbGpPWpGaD
Maraviroc—CCR5—HIV Infection—HLA-A—multiple sclerosis	0.000284	0.00332	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—CCL3—multiple sclerosis	0.000283	0.00331	CbGpPWpGaD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—CXCL10—multiple sclerosis	0.000279	0.00327	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—S1PR1—multiple sclerosis	0.000276	0.00323	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—PTGER4—multiple sclerosis	0.000272	0.00319	CbGpPWpGaD
Maraviroc—CCR5—HIV Life Cycle—CD4—multiple sclerosis	0.000265	0.0031	CbGpPWpGaD
Maraviroc—CCR5—TCR Signaling Pathway—TGFB1—multiple sclerosis	0.000264	0.00309	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—CXCR3—multiple sclerosis	0.000263	0.00308	CbGpPWpGaD
Maraviroc—CCR5—TCR Signaling Pathway—MAPK1—multiple sclerosis	0.000259	0.00303	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—RGS1—multiple sclerosis	0.000259	0.00303	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—CCR2—multiple sclerosis	0.000256	0.00299	CbGpPWpGaD
Maraviroc—CCR5—Peptide ligand-binding receptors—POMC—multiple sclerosis	0.000252	0.00295	CbGpPWpGaD
Maraviroc—CCR5—Peptide ligand-binding receptors—CCL2—multiple sclerosis	0.000247	0.00289	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—GPR65—multiple sclerosis	0.000245	0.00287	CbGpPWpGaD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—CCL5—multiple sclerosis	0.00024	0.00281	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—CNR1—multiple sclerosis	0.000236	0.00276	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—RGS1—multiple sclerosis	0.000235	0.00275	CbGpPWpGaD
Maraviroc—CCR5—Disease—GPC5—multiple sclerosis	0.000227	0.00265	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—CCR1—multiple sclerosis	0.000224	0.00262	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—CXCL13—multiple sclerosis	0.000224	0.00262	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—GPR65—multiple sclerosis	0.000223	0.00261	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—LINGO1—multiple sclerosis	0.000215	0.00252	CbGpPWpGaD
Maraviroc—CCR5—G alpha (i) signalling events—POMC—multiple sclerosis	0.000213	0.00249	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—CXCL10—multiple sclerosis	0.000213	0.00249	CbGpPWpGaD
Maraviroc—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.00021	0.00246	CbGpPWpGaD
Maraviroc—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.00021	0.00246	CbGpPWpGaD
Maraviroc—CYP3A4—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000207	0.00243	CbGpPWpGaD
Maraviroc—CYP3A4—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000207	0.00243	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—CCR1—multiple sclerosis	0.000204	0.00238	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—CXCL13—multiple sclerosis	0.000204	0.00238	CbGpPWpGaD
Maraviroc—CCR5—TCR Signaling Pathway—IL6—multiple sclerosis	0.000199	0.00233	CbGpPWpGaD
Maraviroc—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—multiple sclerosis	0.000189	0.00221	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—TAGAP—multiple sclerosis	0.000187	0.00219	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—CCL5—multiple sclerosis	0.000183	0.00214	CbGpPWpGaD
Maraviroc—CCR5—HIV Infection—CD4—multiple sclerosis	0.000183	0.00214	CbGpPWpGaD
Maraviroc—CYP3A4—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.00017	0.00199	CbGpPWpGaD
Maraviroc—CYP3A4—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.00017	0.00199	CbGpPWpGaD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	0.000169	0.00198	CbGpPWpGaD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	0.000166	0.00194	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—S1PR1—multiple sclerosis	0.000163	0.00191	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—GPC5—multiple sclerosis	0.000159	0.00186	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—PTGER4—multiple sclerosis	0.000154	0.0018	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—CXCR3—multiple sclerosis	0.000149	0.00174	CbGpPWpGaD
Maraviroc—CCR5—Disease—RPL5—multiple sclerosis	0.000147	0.00173	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—CCL3—multiple sclerosis	0.000145	0.0017	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—CCR2—multiple sclerosis	0.000145	0.00169	CbGpPWpGaD
Maraviroc—CCR5—Disease—SLC11A1—multiple sclerosis	0.000141	0.00165	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—PTGER4—multiple sclerosis	0.00014	0.00163	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—RGS1—multiple sclerosis	0.000139	0.00162	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—CXCR3—multiple sclerosis	0.000135	0.00158	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—CNR1—multiple sclerosis	0.000133	0.00156	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—GPR65—multiple sclerosis	0.000132	0.00154	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—CCR2—multiple sclerosis	0.000131	0.00154	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—POMC—multiple sclerosis	0.000129	0.00151	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—CCL2—multiple sclerosis	0.000126	0.00147	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—CNR1—multiple sclerosis	0.000121	0.00142	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CXCL13—multiple sclerosis	0.00012	0.00141	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CCR1—multiple sclerosis	0.00012	0.00141	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—CXCL10—multiple sclerosis	0.00012	0.00141	CbGpPWpGaD
Maraviroc—CCR5—Disease—CD28—multiple sclerosis	0.000113	0.00132	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—CXCL10—multiple sclerosis	0.000109	0.00128	CbGpPWpGaD
Maraviroc—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000108	0.00127	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—CCL5—multiple sclerosis	0.000103	0.00121	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—CCL5—multiple sclerosis	9.39e-05	0.0011	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—IL2RA—multiple sclerosis	9.18e-05	0.00107	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—CYP24A1—multiple sclerosis	9.05e-05	0.00106	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—CYP27B1—multiple sclerosis	9.05e-05	0.00106	CbGpPWpGaD
Maraviroc—CYP3A4—Metapathway biotransformation—CYP24A1—multiple sclerosis	8.93e-05	0.00104	CbGpPWpGaD
Maraviroc—CYP3A4—Metapathway biotransformation—CYP27B1—multiple sclerosis	8.93e-05	0.00104	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CCL3—multiple sclerosis	8.58e-05	0.001	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—IL2RA—multiple sclerosis	8.34e-05	0.000975	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PTGER4—multiple sclerosis	8.26e-05	0.000966	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PGR—multiple sclerosis	8.13e-05	0.000951	CbGpPWpGaD
Maraviroc—CCR5—Disease—CD86—multiple sclerosis	8.05e-05	0.000941	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CXCR3—multiple sclerosis	7.97e-05	0.000933	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CD28—multiple sclerosis	7.9e-05	0.000924	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CCR2—multiple sclerosis	7.76e-05	0.000907	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—POMC—multiple sclerosis	7.28e-05	0.000852	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CNR1—multiple sclerosis	7.16e-05	0.000837	CbGpPWpGaD
Maraviroc—CCR5—Disease—HLA-A—multiple sclerosis	6.96e-05	0.000814	CbGpPWpGaD
Maraviroc—Angiopathy—Dexamethasone—multiple sclerosis	6.84e-05	0.000488	CcSEcCtD
Maraviroc—Convulsion—Prednisolone—multiple sclerosis	6.81e-05	0.000486	CcSEcCtD
Maraviroc—Decreased appetite—Mitoxantrone—multiple sclerosis	6.8e-05	0.000485	CcSEcCtD
Maraviroc—Eosinophilia—Methotrexate—multiple sclerosis	6.79e-05	0.000484	CcSEcCtD
Maraviroc—Fatigue—Mitoxantrone—multiple sclerosis	6.75e-05	0.000481	CcSEcCtD
Maraviroc—Pancreatitis—Methotrexate—multiple sclerosis	6.72e-05	0.000479	CcSEcCtD
Maraviroc—Constipation—Mitoxantrone—multiple sclerosis	6.69e-05	0.000477	CcSEcCtD
Maraviroc—Pain—Mitoxantrone—multiple sclerosis	6.69e-05	0.000477	CcSEcCtD
Maraviroc—Alopecia—Betamethasone—multiple sclerosis	6.66e-05	0.000475	CcSEcCtD
Maraviroc—Alopecia—Dexamethasone—multiple sclerosis	6.66e-05	0.000475	CcSEcCtD
Maraviroc—Diarrhoea—Azathioprine—multiple sclerosis	6.62e-05	0.000472	CcSEcCtD
Maraviroc—Discomfort—Prednisolone—multiple sclerosis	6.62e-05	0.000472	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—POMC—multiple sclerosis	6.61e-05	0.000774	CbGpPWpGaD
Maraviroc—Erythema—Betamethasone—multiple sclerosis	6.56e-05	0.000468	CcSEcCtD
Maraviroc—Erythema—Dexamethasone—multiple sclerosis	6.56e-05	0.000468	CcSEcCtD
Maraviroc—Hallucination—Prednisone—multiple sclerosis	6.53e-05	0.000466	CcSEcCtD
Maraviroc—Pancytopenia—Methotrexate—multiple sclerosis	6.51e-05	0.000464	CcSEcCtD
Maraviroc—CCR5—Disease—APOE—multiple sclerosis	6.49e-05	0.00076	CbGpPWpGaD
Maraviroc—Syncope—Triamcinolone—multiple sclerosis	6.49e-05	0.000463	CcSEcCtD
Maraviroc—Syncope—Methylprednisolone—multiple sclerosis	6.47e-05	0.000462	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—CCL2—multiple sclerosis	6.47e-05	0.000757	CbGpPWpGaD
Maraviroc—Connective tissue disorder—Prednisone—multiple sclerosis	6.45e-05	0.00046	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—CXCL10—multiple sclerosis	6.44e-05	0.000754	CbGpPWpGaD
Maraviroc—Oedema—Prednisolone—multiple sclerosis	6.42e-05	0.000458	CcSEcCtD
Maraviroc—Neutropenia—Methotrexate—multiple sclerosis	6.41e-05	0.000457	CcSEcCtD
Maraviroc—Dizziness—Azathioprine—multiple sclerosis	6.4e-05	0.000456	CcSEcCtD
Maraviroc—Gastrointestinal pain—Mitoxantrone—multiple sclerosis	6.4e-05	0.000456	CcSEcCtD
Maraviroc—Upper respiratory tract infection—Methotrexate—multiple sclerosis	6.37e-05	0.000454	CcSEcCtD
Maraviroc—Loss of consciousness—Triamcinolone—multiple sclerosis	6.36e-05	0.000453	CcSEcCtD
Maraviroc—Loss of consciousness—Methylprednisolone—multiple sclerosis	6.34e-05	0.000452	CcSEcCtD
Maraviroc—Shock—Prednisolone—multiple sclerosis	6.31e-05	0.00045	CcSEcCtD
Maraviroc—Cough—Triamcinolone—multiple sclerosis	6.31e-05	0.00045	CcSEcCtD
Maraviroc—Convulsion—Triamcinolone—multiple sclerosis	6.27e-05	0.000447	CcSEcCtD
Maraviroc—Convulsion—Methylprednisolone—multiple sclerosis	6.25e-05	0.000446	CcSEcCtD
Maraviroc—Abdominal pain—Mitoxantrone—multiple sclerosis	6.18e-05	0.000441	CcSEcCtD
Maraviroc—Body temperature increased—Mitoxantrone—multiple sclerosis	6.18e-05	0.000441	CcSEcCtD
Maraviroc—Myalgia—Triamcinolone—multiple sclerosis	6.16e-05	0.000439	CcSEcCtD
Maraviroc—Vomiting—Azathioprine—multiple sclerosis	6.15e-05	0.000439	CcSEcCtD
Maraviroc—Pneumonia—Methotrexate—multiple sclerosis	6.15e-05	0.000438	CcSEcCtD
Maraviroc—Myalgia—Methylprednisolone—multiple sclerosis	6.14e-05	0.000438	CcSEcCtD
Maraviroc—Eye disorder—Prednisone—multiple sclerosis	6.14e-05	0.000438	CcSEcCtD
Maraviroc—Anxiety—Methylprednisolone—multiple sclerosis	6.12e-05	0.000437	CcSEcCtD
Maraviroc—Infestation—Methotrexate—multiple sclerosis	6.11e-05	0.000436	CcSEcCtD
Maraviroc—Infestation NOS—Methotrexate—multiple sclerosis	6.11e-05	0.000436	CcSEcCtD
Maraviroc—Rash—Azathioprine—multiple sclerosis	6.1e-05	0.000435	CcSEcCtD
Maraviroc—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	6.1e-05	0.000435	CcSEcCtD
Maraviroc—Dermatitis—Azathioprine—multiple sclerosis	6.1e-05	0.000435	CcSEcCtD
Maraviroc—Depression—Methotrexate—multiple sclerosis	6.09e-05	0.000435	CcSEcCtD
Maraviroc—Discomfort—Triamcinolone—multiple sclerosis	6.08e-05	0.000434	CcSEcCtD
Maraviroc—Discomfort—Methylprednisolone—multiple sclerosis	6.07e-05	0.000433	CcSEcCtD
Maraviroc—Headache—Azathioprine—multiple sclerosis	6.06e-05	0.000432	CcSEcCtD
Maraviroc—Stevens-Johnson syndrome—Methotrexate—multiple sclerosis	6.06e-05	0.000432	CcSEcCtD
Maraviroc—Renal failure—Methotrexate—multiple sclerosis	6.01e-05	0.000429	CcSEcCtD
Maraviroc—Stomatitis—Methotrexate—multiple sclerosis	5.96e-05	0.000425	CcSEcCtD
Maraviroc—Angiopathy—Prednisone—multiple sclerosis	5.96e-05	0.000425	CcSEcCtD
Maraviroc—Conjunctivitis—Methotrexate—multiple sclerosis	5.94e-05	0.000424	CcSEcCtD
Maraviroc—Oedema—Triamcinolone—multiple sclerosis	5.9e-05	0.000421	CcSEcCtD
Maraviroc—Syncope—Dexamethasone—multiple sclerosis	5.88e-05	0.00042	CcSEcCtD
Maraviroc—Syncope—Betamethasone—multiple sclerosis	5.88e-05	0.00042	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—TYK2—multiple sclerosis	5.87e-05	0.000687	CbGpPWpGaD
Maraviroc—CCR5—Disease—CD80—multiple sclerosis	5.87e-05	0.000687	CbGpPWpGaD
Maraviroc—Infection—Triamcinolone—multiple sclerosis	5.86e-05	0.000418	CcSEcCtD
Maraviroc—Infection—Methylprednisolone—multiple sclerosis	5.85e-05	0.000417	CcSEcCtD
Maraviroc—Shock—Triamcinolone—multiple sclerosis	5.81e-05	0.000414	CcSEcCtD
Maraviroc—Insomnia—Prednisolone—multiple sclerosis	5.81e-05	0.000414	CcSEcCtD
Maraviroc—Alopecia—Prednisone—multiple sclerosis	5.8e-05	0.000414	CcSEcCtD
Maraviroc—Shock—Methylprednisolone—multiple sclerosis	5.79e-05	0.000413	CcSEcCtD
Maraviroc—Hepatobiliary disease—Methotrexate—multiple sclerosis	5.78e-05	0.000412	CcSEcCtD
Maraviroc—Nervous system disorder—Methylprednisolone—multiple sclerosis	5.78e-05	0.000412	CcSEcCtD
Maraviroc—Loss of consciousness—Dexamethasone—multiple sclerosis	5.77e-05	0.000411	CcSEcCtD
Maraviroc—Loss of consciousness—Betamethasone—multiple sclerosis	5.77e-05	0.000411	CcSEcCtD
Maraviroc—Hypersensitivity—Mitoxantrone—multiple sclerosis	5.76e-05	0.000411	CcSEcCtD
Maraviroc—Paraesthesia—Prednisolone—multiple sclerosis	5.76e-05	0.000411	CcSEcCtD
Maraviroc—Mental disorder—Prednisone—multiple sclerosis	5.75e-05	0.00041	CcSEcCtD
Maraviroc—Nausea—Azathioprine—multiple sclerosis	5.75e-05	0.00041	CcSEcCtD
Maraviroc—Skin disorder—Methylprednisolone—multiple sclerosis	5.72e-05	0.000408	CcSEcCtD
Maraviroc—Malnutrition—Prednisone—multiple sclerosis	5.71e-05	0.000408	CcSEcCtD
Maraviroc—Erythema—Prednisone—multiple sclerosis	5.71e-05	0.000408	CcSEcCtD
Maraviroc—Agranulocytosis—Methotrexate—multiple sclerosis	5.7e-05	0.000407	CcSEcCtD
Maraviroc—Convulsion—Dexamethasone—multiple sclerosis	5.69e-05	0.000406	CcSEcCtD
Maraviroc—Convulsion—Betamethasone—multiple sclerosis	5.69e-05	0.000406	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—CD86—multiple sclerosis	5.64e-05	0.000659	CbGpPWpGaD
Maraviroc—Asthenia—Mitoxantrone—multiple sclerosis	5.61e-05	0.0004	CcSEcCtD
Maraviroc—Myalgia—Dexamethasone—multiple sclerosis	5.59e-05	0.000399	CcSEcCtD
Maraviroc—Myalgia—Betamethasone—multiple sclerosis	5.59e-05	0.000399	CcSEcCtD
Maraviroc—Anxiety—Dexamethasone—multiple sclerosis	5.57e-05	0.000397	CcSEcCtD
Maraviroc—Anxiety—Betamethasone—multiple sclerosis	5.57e-05	0.000397	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—CCL5—multiple sclerosis	5.55e-05	0.000649	CbGpPWpGaD
Maraviroc—Discomfort—Betamethasone—multiple sclerosis	5.52e-05	0.000394	CcSEcCtD
Maraviroc—Discomfort—Dexamethasone—multiple sclerosis	5.52e-05	0.000394	CcSEcCtD
Maraviroc—Pain—Prednisolone—multiple sclerosis	5.49e-05	0.000392	CcSEcCtD
Maraviroc—Pharyngitis—Methotrexate—multiple sclerosis	5.45e-05	0.000388	CcSEcCtD
Maraviroc—Urinary tract disorder—Methotrexate—multiple sclerosis	5.42e-05	0.000386	CcSEcCtD
Maraviroc—CCR5—GPCR downstream signaling—IL2—multiple sclerosis	5.38e-05	0.00063	CbGpPWpGaD
Maraviroc—Urethral disorder—Methotrexate—multiple sclerosis	5.38e-05	0.000384	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	5.38e-05	0.000384	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	5.37e-05	0.000383	CcSEcCtD
Maraviroc—Oedema—Betamethasone—multiple sclerosis	5.36e-05	0.000382	CcSEcCtD
Maraviroc—Oedema—Dexamethasone—multiple sclerosis	5.36e-05	0.000382	CcSEcCtD
Maraviroc—Diarrhoea—Mitoxantrone—multiple sclerosis	5.35e-05	0.000382	CcSEcCtD
Maraviroc—Insomnia—Triamcinolone—multiple sclerosis	5.34e-05	0.000381	CcSEcCtD
Maraviroc—Insomnia—Methylprednisolone—multiple sclerosis	5.33e-05	0.00038	CcSEcCtD
Maraviroc—Infection—Betamethasone—multiple sclerosis	5.32e-05	0.00038	CcSEcCtD
Maraviroc—Infection—Dexamethasone—multiple sclerosis	5.32e-05	0.00038	CcSEcCtD
Maraviroc—Paraesthesia—Triamcinolone—multiple sclerosis	5.3e-05	0.000378	CcSEcCtD
Maraviroc—Paraesthesia—Methylprednisolone—multiple sclerosis	5.29e-05	0.000377	CcSEcCtD
Maraviroc—Anaemia—Prednisone—multiple sclerosis	5.28e-05	0.000377	CcSEcCtD
Maraviroc—Shock—Dexamethasone—multiple sclerosis	5.27e-05	0.000376	CcSEcCtD
Maraviroc—Shock—Betamethasone—multiple sclerosis	5.27e-05	0.000376	CcSEcCtD
Maraviroc—Nervous system disorder—Dexamethasone—multiple sclerosis	5.25e-05	0.000375	CcSEcCtD
Maraviroc—Nervous system disorder—Betamethasone—multiple sclerosis	5.25e-05	0.000375	CcSEcCtD
Maraviroc—Erythema multiforme—Methotrexate—multiple sclerosis	5.19e-05	0.00037	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—SPP1—multiple sclerosis	5.14e-05	0.000601	CbGpPWpGaD
Maraviroc—Eye disorder—Methotrexate—multiple sclerosis	5.13e-05	0.000366	CcSEcCtD
Maraviroc—Syncope—Prednisone—multiple sclerosis	5.12e-05	0.000366	CcSEcCtD
Maraviroc—Anorexia—Dexamethasone—multiple sclerosis	5.11e-05	0.000364	CcSEcCtD
Maraviroc—Anorexia—Betamethasone—multiple sclerosis	5.11e-05	0.000364	CcSEcCtD
Maraviroc—Cardiac disorder—Methotrexate—multiple sclerosis	5.09e-05	0.000363	CcSEcCtD
Maraviroc—Fatigue—Triamcinolone—multiple sclerosis	5.09e-05	0.000363	CcSEcCtD
Maraviroc—Fatigue—Methylprednisolone—multiple sclerosis	5.08e-05	0.000362	CcSEcCtD
Maraviroc—Pain—Triamcinolone—multiple sclerosis	5.05e-05	0.00036	CcSEcCtD
Maraviroc—Loss of consciousness—Prednisone—multiple sclerosis	5.02e-05	0.000358	CcSEcCtD
Maraviroc—Angiopathy—Methotrexate—multiple sclerosis	4.98e-05	0.000355	CcSEcCtD
Maraviroc—Vomiting—Mitoxantrone—multiple sclerosis	4.97e-05	0.000355	CcSEcCtD
Maraviroc—CCR5—Disease—TYK2—multiple sclerosis	4.96e-05	0.00058	CbGpPWpGaD
Maraviroc—Convulsion—Prednisone—multiple sclerosis	4.95e-05	0.000353	CcSEcCtD
Maraviroc—Mediastinal disorder—Methotrexate—multiple sclerosis	4.94e-05	0.000353	CcSEcCtD
Maraviroc—Rash—Mitoxantrone—multiple sclerosis	4.93e-05	0.000352	CcSEcCtD
Maraviroc—Dermatitis—Mitoxantrone—multiple sclerosis	4.93e-05	0.000352	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—IL2RA—multiple sclerosis	4.93e-05	0.000576	CbGpPWpGaD
Maraviroc—Headache—Mitoxantrone—multiple sclerosis	4.9e-05	0.00035	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—IL2—multiple sclerosis	4.89e-05	0.000572	CbGpPWpGaD
Maraviroc—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	4.88e-05	0.000348	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	4.88e-05	0.000348	CcSEcCtD
Maraviroc—Myalgia—Prednisone—multiple sclerosis	4.87e-05	0.000347	CcSEcCtD
Maraviroc—Anxiety—Prednisone—multiple sclerosis	4.85e-05	0.000346	CcSEcCtD
Maraviroc—Alopecia—Methotrexate—multiple sclerosis	4.85e-05	0.000346	CcSEcCtD
Maraviroc—Insomnia—Dexamethasone—multiple sclerosis	4.84e-05	0.000346	CcSEcCtD
Maraviroc—Insomnia—Betamethasone—multiple sclerosis	4.84e-05	0.000346	CcSEcCtD
Maraviroc—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	4.83e-05	0.000345	CcSEcCtD
Maraviroc—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	4.82e-05	0.000344	CcSEcCtD
Maraviroc—Paraesthesia—Betamethasone—multiple sclerosis	4.81e-05	0.000343	CcSEcCtD
Maraviroc—Paraesthesia—Dexamethasone—multiple sclerosis	4.81e-05	0.000343	CcSEcCtD
Maraviroc—Discomfort—Prednisone—multiple sclerosis	4.81e-05	0.000343	CcSEcCtD
Maraviroc—Mental disorder—Methotrexate—multiple sclerosis	4.81e-05	0.000343	CcSEcCtD
Maraviroc—Erythema—Methotrexate—multiple sclerosis	4.78e-05	0.000341	CcSEcCtD
Maraviroc—Malnutrition—Methotrexate—multiple sclerosis	4.78e-05	0.000341	CcSEcCtD
Maraviroc—Hypersensitivity—Prednisolone—multiple sclerosis	4.73e-05	0.000337	CcSEcCtD
Maraviroc—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	4.73e-05	0.000553	CbGpPWpGaD
Maraviroc—Body temperature increased—Triamcinolone—multiple sclerosis	4.67e-05	0.000333	CcSEcCtD
Maraviroc—Oedema—Prednisone—multiple sclerosis	4.66e-05	0.000333	CcSEcCtD
Maraviroc—Abdominal pain—Methylprednisolone—multiple sclerosis	4.66e-05	0.000332	CcSEcCtD
Maraviroc—Decreased appetite—Betamethasone—multiple sclerosis	4.66e-05	0.000332	CcSEcCtD
Maraviroc—Decreased appetite—Dexamethasone—multiple sclerosis	4.66e-05	0.000332	CcSEcCtD
Maraviroc—Nausea—Mitoxantrone—multiple sclerosis	4.65e-05	0.000331	CcSEcCtD
Maraviroc—Infection—Prednisone—multiple sclerosis	4.63e-05	0.000331	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	4.62e-05	0.00033	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Betamethasone—multiple sclerosis	4.62e-05	0.00033	CcSEcCtD
Maraviroc—Fatigue—Dexamethasone—multiple sclerosis	4.62e-05	0.000329	CcSEcCtD
Maraviroc—Fatigue—Betamethasone—multiple sclerosis	4.62e-05	0.000329	CcSEcCtD
Maraviroc—Shock—Prednisone—multiple sclerosis	4.59e-05	0.000327	CcSEcCtD
Maraviroc—Pain—Dexamethasone—multiple sclerosis	4.58e-05	0.000327	CcSEcCtD
Maraviroc—Pain—Betamethasone—multiple sclerosis	4.58e-05	0.000327	CcSEcCtD
Maraviroc—Nervous system disorder—Prednisone—multiple sclerosis	4.57e-05	0.000326	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—APOE—multiple sclerosis	4.55e-05	0.000532	CbGpPWpGaD
Maraviroc—Skin disorder—Prednisone—multiple sclerosis	4.53e-05	0.000323	CcSEcCtD
Maraviroc—CCR5—Disease—CD4—multiple sclerosis	4.48e-05	0.000524	CbGpPWpGaD
Maraviroc—Anorexia—Prednisone—multiple sclerosis	4.45e-05	0.000317	CcSEcCtD
Maraviroc—Anaemia—Methotrexate—multiple sclerosis	4.41e-05	0.000315	CcSEcCtD
Maraviroc—Gastrointestinal pain—Dexamethasone—multiple sclerosis	4.38e-05	0.000312	CcSEcCtD
Maraviroc—Gastrointestinal pain—Betamethasone—multiple sclerosis	4.38e-05	0.000312	CcSEcCtD
Maraviroc—Hypersensitivity—Triamcinolone—multiple sclerosis	4.35e-05	0.00031	CcSEcCtD
Maraviroc—Hypersensitivity—Methylprednisolone—multiple sclerosis	4.34e-05	0.00031	CcSEcCtD
Maraviroc—CYP3A4—nervous system—multiple sclerosis	4.31e-05	0.0245	CbGeAlD
Maraviroc—Leukopenia—Methotrexate—multiple sclerosis	4.28e-05	0.000305	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Prednisone—multiple sclerosis	4.25e-05	0.000303	CcSEcCtD
Maraviroc—Dizziness—Prednisolone—multiple sclerosis	4.24e-05	0.000303	CcSEcCtD
Maraviroc—Asthenia—Triamcinolone—multiple sclerosis	4.23e-05	0.000302	CcSEcCtD
Maraviroc—Body temperature increased—Dexamethasone—multiple sclerosis	4.23e-05	0.000302	CcSEcCtD
Maraviroc—Body temperature increased—Betamethasone—multiple sclerosis	4.23e-05	0.000302	CcSEcCtD
Maraviroc—Abdominal pain—Dexamethasone—multiple sclerosis	4.23e-05	0.000302	CcSEcCtD
Maraviroc—Abdominal pain—Betamethasone—multiple sclerosis	4.23e-05	0.000302	CcSEcCtD
Maraviroc—Asthenia—Methylprednisolone—multiple sclerosis	4.23e-05	0.000301	CcSEcCtD
Maraviroc—Insomnia—Prednisone—multiple sclerosis	4.22e-05	0.000301	CcSEcCtD
Maraviroc—Paraesthesia—Prednisone—multiple sclerosis	4.19e-05	0.000299	CcSEcCtD
Maraviroc—Pruritus—Triamcinolone—multiple sclerosis	4.18e-05	0.000298	CcSEcCtD
Maraviroc—Cough—Methotrexate—multiple sclerosis	4.17e-05	0.000297	CcSEcCtD
Maraviroc—Pruritus—Methylprednisolone—multiple sclerosis	4.17e-05	0.000297	CcSEcCtD
Maraviroc—CYP3A4—central nervous system—multiple sclerosis	4.15e-05	0.0236	CbGeAlD
Maraviroc—Convulsion—Methotrexate—multiple sclerosis	4.14e-05	0.000295	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—CD80—multiple sclerosis	4.11e-05	0.000481	CbGpPWpGaD
Maraviroc—Myalgia—Methotrexate—multiple sclerosis	4.07e-05	0.00029	CcSEcCtD
Maraviroc—Decreased appetite—Prednisone—multiple sclerosis	4.05e-05	0.000289	CcSEcCtD
Maraviroc—Rash—Prednisolone—multiple sclerosis	4.05e-05	0.000289	CcSEcCtD
Maraviroc—Dermatitis—Prednisolone—multiple sclerosis	4.04e-05	0.000288	CcSEcCtD
Maraviroc—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	4.04e-05	0.000288	CcSEcCtD
Maraviroc—Diarrhoea—Methylprednisolone—multiple sclerosis	4.03e-05	0.000287	CcSEcCtD
Maraviroc—Fatigue—Prednisone—multiple sclerosis	4.02e-05	0.000287	CcSEcCtD
Maraviroc—Headache—Prednisolone—multiple sclerosis	4.02e-05	0.000287	CcSEcCtD
Maraviroc—Discomfort—Methotrexate—multiple sclerosis	4.02e-05	0.000287	CcSEcCtD
Maraviroc—Constipation—Prednisone—multiple sclerosis	3.99e-05	0.000284	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—POMC—multiple sclerosis	3.91e-05	0.000457	CbGpPWpGaD
Maraviroc—Dizziness—Triamcinolone—multiple sclerosis	3.9e-05	0.000278	CcSEcCtD
Maraviroc—Dizziness—Methylprednisolone—multiple sclerosis	3.89e-05	0.000278	CcSEcCtD
Maraviroc—Infection—Methotrexate—multiple sclerosis	3.87e-05	0.000276	CcSEcCtD
Maraviroc—Asthenia—Betamethasone—multiple sclerosis	3.84e-05	0.000274	CcSEcCtD
Maraviroc—Asthenia—Dexamethasone—multiple sclerosis	3.84e-05	0.000274	CcSEcCtD
Maraviroc—CYP3A4—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	3.83e-05	0.000448	CbGpPWpGaD
Maraviroc—Nervous system disorder—Methotrexate—multiple sclerosis	3.82e-05	0.000273	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—CCL2—multiple sclerosis	3.82e-05	0.000447	CbGpPWpGaD
Maraviroc—Gastrointestinal pain—Prednisone—multiple sclerosis	3.81e-05	0.000272	CcSEcCtD
Maraviroc—Nausea—Prednisolone—multiple sclerosis	3.81e-05	0.000272	CcSEcCtD
Maraviroc—Pruritus—Dexamethasone—multiple sclerosis	3.79e-05	0.00027	CcSEcCtD
Maraviroc—Pruritus—Betamethasone—multiple sclerosis	3.79e-05	0.00027	CcSEcCtD
Maraviroc—Skin disorder—Methotrexate—multiple sclerosis	3.79e-05	0.00027	CcSEcCtD
Maraviroc—Vomiting—Triamcinolone—multiple sclerosis	3.75e-05	0.000268	CcSEcCtD
Maraviroc—Vomiting—Methylprednisolone—multiple sclerosis	3.74e-05	0.000267	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—MAPK1—multiple sclerosis	3.74e-05	0.000437	CbGpPWpGaD
Maraviroc—Rash—Triamcinolone—multiple sclerosis	3.72e-05	0.000265	CcSEcCtD
Maraviroc—Dermatitis—Triamcinolone—multiple sclerosis	3.72e-05	0.000265	CcSEcCtD
Maraviroc—Anorexia—Methotrexate—multiple sclerosis	3.72e-05	0.000265	CcSEcCtD
Maraviroc—Rash—Methylprednisolone—multiple sclerosis	3.71e-05	0.000265	CcSEcCtD
Maraviroc—Dermatitis—Methylprednisolone—multiple sclerosis	3.71e-05	0.000265	CcSEcCtD
Maraviroc—Headache—Triamcinolone—multiple sclerosis	3.7e-05	0.000264	CcSEcCtD
Maraviroc—Headache—Methylprednisolone—multiple sclerosis	3.69e-05	0.000263	CcSEcCtD
Maraviroc—Abdominal pain—Prednisone—multiple sclerosis	3.69e-05	0.000263	CcSEcCtD
Maraviroc—Body temperature increased—Prednisone—multiple sclerosis	3.69e-05	0.000263	CcSEcCtD
Maraviroc—Diarrhoea—Dexamethasone—multiple sclerosis	3.66e-05	0.000261	CcSEcCtD
Maraviroc—Diarrhoea—Betamethasone—multiple sclerosis	3.66e-05	0.000261	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	3.55e-05	0.000253	CcSEcCtD
Maraviroc—Dizziness—Betamethasone—multiple sclerosis	3.54e-05	0.000253	CcSEcCtD
Maraviroc—Dizziness—Dexamethasone—multiple sclerosis	3.54e-05	0.000253	CcSEcCtD
Maraviroc—Insomnia—Methotrexate—multiple sclerosis	3.53e-05	0.000251	CcSEcCtD
Maraviroc—Nausea—Triamcinolone—multiple sclerosis	3.51e-05	0.00025	CcSEcCtD
Maraviroc—Paraesthesia—Methotrexate—multiple sclerosis	3.5e-05	0.00025	CcSEcCtD
Maraviroc—Nausea—Methylprednisolone—multiple sclerosis	3.5e-05	0.00025	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—TYK2—multiple sclerosis	3.47e-05	0.000406	CbGpPWpGaD
Maraviroc—CCR5—Disease—STAT3—multiple sclerosis	3.47e-05	0.000406	CbGpPWpGaD
Maraviroc—Hypersensitivity—Prednisone—multiple sclerosis	3.44e-05	0.000245	CcSEcCtD
Maraviroc—Vomiting—Betamethasone—multiple sclerosis	3.41e-05	0.000243	CcSEcCtD
Maraviroc—Vomiting—Dexamethasone—multiple sclerosis	3.41e-05	0.000243	CcSEcCtD
Maraviroc—Decreased appetite—Methotrexate—multiple sclerosis	3.39e-05	0.000242	CcSEcCtD
Maraviroc—Rash—Dexamethasone—multiple sclerosis	3.38e-05	0.000241	CcSEcCtD
Maraviroc—Rash—Betamethasone—multiple sclerosis	3.38e-05	0.000241	CcSEcCtD
Maraviroc—Dermatitis—Betamethasone—multiple sclerosis	3.37e-05	0.000241	CcSEcCtD
Maraviroc—Dermatitis—Dexamethasone—multiple sclerosis	3.37e-05	0.000241	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Methotrexate—multiple sclerosis	3.37e-05	0.00024	CcSEcCtD
Maraviroc—Fatigue—Methotrexate—multiple sclerosis	3.36e-05	0.00024	CcSEcCtD
Maraviroc—Headache—Betamethasone—multiple sclerosis	3.36e-05	0.000239	CcSEcCtD
Maraviroc—Headache—Dexamethasone—multiple sclerosis	3.36e-05	0.000239	CcSEcCtD
Maraviroc—Asthenia—Prednisone—multiple sclerosis	3.35e-05	0.000239	CcSEcCtD
Maraviroc—Pain—Methotrexate—multiple sclerosis	3.33e-05	0.000238	CcSEcCtD
Maraviroc—Pruritus—Prednisone—multiple sclerosis	3.3e-05	0.000235	CcSEcCtD
Maraviroc—CCR5—Disease—MYC—multiple sclerosis	3.22e-05	0.000377	CbGpPWpGaD
Maraviroc—CCR5—Disease—TGFB1—multiple sclerosis	3.22e-05	0.000376	CbGpPWpGaD
Maraviroc—Diarrhoea—Prednisone—multiple sclerosis	3.19e-05	0.000228	CcSEcCtD
Maraviroc—Gastrointestinal pain—Methotrexate—multiple sclerosis	3.19e-05	0.000227	CcSEcCtD
Maraviroc—Nausea—Betamethasone—multiple sclerosis	3.18e-05	0.000227	CcSEcCtD
Maraviroc—Nausea—Dexamethasone—multiple sclerosis	3.18e-05	0.000227	CcSEcCtD
Maraviroc—CCR5—Disease—MAPK1—multiple sclerosis	3.15e-05	0.000369	CbGpPWpGaD
Maraviroc—Dizziness—Prednisone—multiple sclerosis	3.08e-05	0.00022	CcSEcCtD
Maraviroc—Abdominal pain—Methotrexate—multiple sclerosis	3.08e-05	0.00022	CcSEcCtD
Maraviroc—Body temperature increased—Methotrexate—multiple sclerosis	3.08e-05	0.00022	CcSEcCtD
Maraviroc—Vomiting—Prednisone—multiple sclerosis	2.97e-05	0.000212	CcSEcCtD
Maraviroc—Rash—Prednisone—multiple sclerosis	2.94e-05	0.00021	CcSEcCtD
Maraviroc—Dermatitis—Prednisone—multiple sclerosis	2.94e-05	0.00021	CcSEcCtD
Maraviroc—Headache—Prednisone—multiple sclerosis	2.92e-05	0.000208	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—IL2—multiple sclerosis	2.89e-05	0.000338	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—IL6—multiple sclerosis	2.87e-05	0.000336	CbGpPWpGaD
Maraviroc—Hypersensitivity—Methotrexate—multiple sclerosis	2.87e-05	0.000205	CcSEcCtD
Maraviroc—Asthenia—Methotrexate—multiple sclerosis	2.8e-05	0.000199	CcSEcCtD
Maraviroc—Nausea—Prednisone—multiple sclerosis	2.77e-05	0.000198	CcSEcCtD
Maraviroc—Pruritus—Methotrexate—multiple sclerosis	2.76e-05	0.000197	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—MMP9—multiple sclerosis	2.73e-05	0.00032	CbGpPWpGaD
Maraviroc—Diarrhoea—Methotrexate—multiple sclerosis	2.67e-05	0.00019	CcSEcCtD
Maraviroc—Dizziness—Methotrexate—multiple sclerosis	2.58e-05	0.000184	CcSEcCtD
Maraviroc—Vomiting—Methotrexate—multiple sclerosis	2.48e-05	0.000177	CcSEcCtD
Maraviroc—Rash—Methotrexate—multiple sclerosis	2.46e-05	0.000175	CcSEcCtD
Maraviroc—Dermatitis—Methotrexate—multiple sclerosis	2.46e-05	0.000175	CcSEcCtD
Maraviroc—Headache—Methotrexate—multiple sclerosis	2.44e-05	0.000174	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—STAT3—multiple sclerosis	2.43e-05	0.000284	CbGpPWpGaD
Maraviroc—CCR5—Disease—IL6—multiple sclerosis	2.42e-05	0.000284	CbGpPWpGaD
Maraviroc—Nausea—Methotrexate—multiple sclerosis	2.32e-05	0.000165	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—MYC—multiple sclerosis	2.26e-05	0.000264	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—TGFB1—multiple sclerosis	2.25e-05	0.000264	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—MAPK1—multiple sclerosis	2.21e-05	0.000258	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—SRM—multiple sclerosis	2.2e-05	0.000257	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—POMC—multiple sclerosis	2.04e-05	0.000238	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—IL6—multiple sclerosis	1.7e-05	0.000199	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	1.55e-05	0.000181	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	1.55e-05	0.000181	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GPC5—multiple sclerosis	1.42e-05	0.000166	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—RRM1—multiple sclerosis	1.17e-05	0.000137	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—BCHE—multiple sclerosis	6.74e-06	7.88e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—APOE—multiple sclerosis	4.05e-06	4.74e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—POMC—multiple sclerosis	3.48e-06	4.07e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ALB—multiple sclerosis	3.17e-06	3.71e-05	CbGpPWpGaD
